Clinical and microbiological features of tedizolid - new representative of oxazolidinone group


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The literature review presents the results of studies of a new representative of oxazolidinones, tedizolid phosphate, registered in the Russian Federation in 2016. The article discusses the mechanism of antibacterial action, pharmacokinetic and pharmacodynamic parameters. According to international studies, tedizolid phosphate has a high activity against Gram-positive microorganisms, such as Staphylococcus aureus (strains of S. aureus, including methicillin-resistant strains), Streptococcus pyogenes, Str. agalactiae, Str. anginosus and Enterococcus faecalis, including strains that develop resistance mechanisms and limit the use of linezolid. The results of randomized controlled phase III trials (ESTABLISH-1 and ESTABLISH-2) demonstrate that the administration of this antibacterial agent at a dose of 200 mg (intravenous or per os) once a day for 6 days is not less effective than a 10-day course of linezolid therapy (600 mg twice a day) in patients with acute bacterial skin and skin-structure infection. Along with the high clinical and microbiological efficacy, tedizolid phosphate is characterized by a good safety and tolerability profile, and can therefore be considered as a treatment option for patients with complicated skin and soft tissue infection in outpatient or inpatient care settings.

Full Text

Restricted Access

About the authors

V. V Nikoda

FSBIS “Russian Scientific Center for Surgery n.a. Acad. B.V. Petrovsky"

Email: nikoda2004@mail.ru
MD, Head of the Department of Resuscitation and Intensive Care-I

S. M Kuznetsova

FSBIS “Russian Scientific Center for Surgery n.a. Acad. B.V. Petrovsky"

A. S Prusova

FSBIS “Russian Scientific Center for Surgery n.a. Acad. B.V. Petrovsky"

References

  1. Белобородов В.Б. Современные принципы применения левофлоксацина в лечении инфекций кожи мягких тканей. Consilium medicum 2009;1:38-42.
  2. Инструкция по применению лекарственного препарата для медицинского применения. Сивекстро. Регистрационный номер: ЛП-003660). Sivextro (tedizolid phosphate) tablet or for injection [prescribing information]. Lexington, MA: Cubist Pharmaceuticals US; June 2014.
  3. Никулин А.А. Обзор рекомендаций Британского общества по антимикробной химиотерапии (BSAC) по диагностике и лечению инфекций, вызванных штаммами MRSA. КМАХ. 2010;12,(1):4-22.
  4. Хирургические инфекции кожи и мягких тканей. Росс. национальные рекомендации. Руководство под ред. В.С. Савельева. М., 2009.
  5. Яковлев С.В. Линезолид - первый препарат нового класса антимикробных средств оксаолидинонов: перспективы лечения грамположительных инфекций. Инфекции и антимикробная терапия 2001;3(6):169-74.
  6. Drusano G.L., Liu W., Kulawy R., Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 2011;55(11):5300-305.
  7. Flanagan S., Fang E., Munoz K.A., Minassian S.L., Prokocimer P.G. Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid. Pharmacotherapy. 2014;34:891-900.
  8. Flanagan S., McKee E.E., Das D., et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015;59(1):178-85.
  9. Flanagan S, Minassian S.L., Morris D., Ponnuraj R., Marbury T.C., Alcorn H.W., Fang E., Prokocimer P. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014;58(11):6471-76.
  10. Flanagan S., Minassian S.L., Passarell J., Fiedler-Kelly J., Prokocimer P. Tedizolid plasma pharmacokinetics are comparable in obese and nonobese patients and healty patients [Abstract P1703]. Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases; May 10-13; 2014; Barcelona, Spain.
  11. Flanagan S., Passarell J., Lu Q., Fiedler-Kelly J., Ludwig E., Prokocimer P. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother. 2014;58(11):6462-70.
  12. Flanagan S.D., Bien P.A., Munoz K.A., Minassian S.L., Prokocimer P.G. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014;34(3):240-50.
  13. Housman S.T.,Pope J.S.,Russomanno J.,Salerno E., Shore E., Kuti J.L., Nicolau D.P. Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers. Antimicrobial Agents and Chemotherapy. 2012;56(5):2627-34.
  14. Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H. Discovery of torezolid as anovel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur. J. Medicine Chem. 2011;46(4):1027-39.
  15. Klein E., Smith D.L., Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 2007;13:1840-46.
  16. Chen K.H., Huang Y.T., Liao C.H., Sheng W.H., Hsuehd PR. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia. Antimicr. Agent Chemotherapy. 2015;59(10):6262-65.
  17. Kozlov R.S., Krechikova O.I., Ivanchik N.V et.al. Etiology of Nosocomial Bacterial Infections in Russia. Rosnet Study Group. Procedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008;Washington, USA. Р 572, abst.K-4108.
  18. Leach K.L., Swaney S.M., Colca J.R., McDonald W.G., Blinn J.R., Thomasco L.M., Gadwood R.C., Shinabarger D., Xiong L., Mankin A.S. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell. 2007;26(3):393-402.
  19. Lemaire S., Van Bambeke F., Appelbaum P.C., Tulkens P.M. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J. Antimicrob. Chemother. 2009;64(5):1035-43.
  20. LockeJ.B.,FinnJ.,Hilgers M.,Morales G.,Rahawi S., Kedar G.C., Picazo J.J., Im W., Shaw K.J., Stein J.L. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 2010;54(12):5337-43.
  21. Locke J.B., Hilgers M., Shaw K.J. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 2009;53: 5265-74.
  22. Locke J.B., Morales G., Hilgers M., et al. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob Agents Chemother 2010;54(12):5352-55.
  23. Locke J.B., Zurenko G.E., Shaw K.J., Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014;58(Suppl 1):S35-42.
  24. Lodise T.P., Fang E., Minassian S.L., Prokocimer P.G. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob. Agents Chemother. 2014;58(12):7198-204.
  25. May AK. Skin and soft tissue infections. Surg. Clin. North Am. 2009;89(2):403-20.
  26. McCool R., Gould I. M., Eales J., Barata T, Arber M., Fleetwood K., Glanville J. and Kauf T. L. Systematic review and network meta- analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infectious Diseases. 2017;17(39):2-11.
  27. Morales G., Picazo J.J., Baos E., Candel F.J., Arribi A., Pelaez B., Andrade R., de la Torre M.A., Fereres J., Sanchez-Garcia M. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 2010;50(6):821-25.
  28. Moran G.J., Fang E., Corey G.R., Das A.F., De Anda C., Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696-705.
  29. Ong V., Flanagan.S, Fang E., Dreskin H.J., Locke J.B., Bartizal K., Prokocimer P Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab. Dispos. 2014;42(8):1275-84.
  30. Posnett Y., Gottrup F., Luındgren H. Saal G. The resource impact of wounds on health-care providers in Europe. J. Wound Care. 2009;18(4):154.
  31. Prokocimer P., Bien.P, Deanda C., Pillar C.M., Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Grampositive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(9):4608-13.
  32. Prokocimer P., Bien P, Munoz K.A., Aster R. Haematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects [Abstract A-2069]. Poster presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotheraphy; October 25-28; 2008; Washington, DC.
  33. Prokocimer P., De Anda C., Fang E., Mehra P., Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559-69.
  34. Pulgar S., Mehra M., Quintana A., et al. The epidemiology of hospitalized cases of skin and soft tissue infection in Europe. 18th European Congress of Clinical Microbiology and infectious diseases. 2008,Barcelona, Spain. Abstr. P. 821.
  35. Reyes Y, Rincon S., Diaz L., Panesso D., Contreras G.A., Zurita J., Carrillo C., Rizzi A., Guzman M., Adachi J., Chowdhury S., Murray B.E., Arias C.A. Dissemination of methycillin-resistant Staphylococcus USA300 sequenct type 8 lineage in Latin America. Clin. Infect. Dis. 2009;49(12):1861-67.
  36. Sahm D.F., Deane J., Bien P.A., Locke J.B., Zuill D.E., Shaw K.J., Bartizal K.F. Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from theUnited States and Europe. Diagn. Microbiol. Infect. Dis. 2015;81(2):112-18.
  37. Schaadt R., Sweeney D., Shinabarger D., Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 2009;53(8):3236-39.
  38. Schlosser M.J., Hosako H., Radovsky A., Butt M.T., Draganov D., Vija J., Oleson F. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months. Antimicrob. Agents Chemother. 2015;59(1):475-81.
  39. Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann. N Y Acad. Sci. 2011;1241:48-70.
  40. Shaw K.J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C.M., Shinabarger D., Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 2008;52(12):4442-47.
  41. Shorr A.F., Lodise T.P, Corey G.R., De Anda C., Fang E., Das A.F., Prokocimer Ph. Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 2015;59:864-71.
  42. Lee Y., Hong S.K., Choi S.H., Im W., Yong D., Lee K., et al. In vitro Activity of Tedizolid against Grampositive Bacteria in Patiens with Skin and Skin Structure Infections and Hospital-Acquired Pneumoniae; A Korean Multicenter Study. Ann. Lab. Med. 2015;35:523-30.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies